A.

Study [Ref.]	Ethnicity	N biopsy class	Age, years mean ± SD	Total number	Treatment	Standard of care	Patients, n	Follow-up period
Furie, 2022 [27]	Mixeda	III, IV, V	33.1±9.8	125	Obinutuzumab	MMF	63	104 weeks
					Control		62
Jayne, 2022 [28]	European	III, IV, V	35.0 (18–65)b	132	Anifrolumab	MMF	87	52 weeks
					Control		45
Furie, 2020 [25]	Mixedc	III, IV, V	33.7±10.7	446	Belimumab	CYC or MMF	223	104 weeks
					Control		223
He, 2020 [26]	Asian	Biopsy-proven LN	31.58±9.25	25	Low-dose IL-2	CYC, MMF, or other immunosuppressantsd	13	24 weeks
					Control		12
Zhang, 2015 [24]		III, IV, V			Rituximab	CYC	42	12 months
					Control		42
ACCESS, 2014 [22]	Mixede	III, IV, V	32.0±10.1	134	Abatacept	CYC	66	24 weeks
					Control		68
Furie, 2014 [22]	Mixedf	III, IV, V	31.0±9.5	199	Abatacept	MMF	99	52 weeks
					Control		100
Mysler, 2013 [21]	Mixedg	III, IV, V	31.3 (16–69)b	223	Ocrelizumab	CYC or MMF	148	48 weeks
					Control		75
Rovin, 2012 [20]	Mixedh	III, IV, V	31.8±9.6	144	Rituximab	MMF	72	78 weeks
					Control		72